Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

by | Oct 14, 2025 | Clinical Trials | 0 comments

​ Conditions: Immune Thrombocytopenia

Interventions: Drug: rilzabrutinib

Sponsors: Sanofi

Not yet recruiting Conditions: Immune Thrombocytopenia
Interventions: Drug: rilzabrutinib
Sponsors: Sanofi
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *